US OptionsDetailed Quotes
PFE240726P40000
- 9.20
- -0.34-3.56%
15min DelayTrading Jul 26 13:52 ET
9.54High9.20Low
9.54Open9.54Pre Close2 Volume0 Open Interest40.00Strike Price1.87KTurnover0.00%IV0.00%PremiumJul 26, 2024Expiry Date9.20Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.50Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
PFE us at resistance, 30.70
Earnings soon, stars aligned
above 50 EMA
When PFE turns, it will move hard and fast. a lot of pressure has been built up over the 1.5-year drop.
This treatment for patients with hemophilia A appears to have the efficacy and safety metrics in place to warrant a potential approval.
Notably, Sangamo’s candidate is being developed alongside $Pfizer(PFE.US)$ , adding a layer of clout to the R&D behind the prospective treatment.
Sneaking on the radar on a red day.
No comment yet